Santen Pharmaceutical said on March 31 that it has grabbed the backing of a key European regulatory panel for its low-dose atropine ophthalmic formulation Ryjunea (atropine sulfate) for slowing the progression of pediatric myopia.The European Medicines Agency’s (EMA) Committee for…
To read the full story
Related Article
- Santen’s Myopia Drug Ryjunea Now Available in Germany
July 23, 2025
- Santen’s Myopia Drug Approved in Europe
June 6, 2025
BUSINESS
- Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
- Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
- Expert Welcomes Talvey-Tecvayli Combo for Difficult-to-Treat MM
July 10, 2026
- Axcelead Teams Up with Mitsubishi to Expand Drug Discovery Support Biz
July 10, 2026
- Roche PD-L1 Test Approved for Imfinzi in Endometrial Cancer
July 10, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





